Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans

Using a derivation cohort (N=349), we developed the first warfarin dosing algorithm that includes recently discovered polymorphisms in VKORC1 and CYP2C9 associated with warfarin dose requirement in African Americans (AAs). We tested our novel algorithm in an independent cohort of 129 AAs and compared the dose prediction to the International Warfarin Pharmacogenetics Consortium (IWPC) dosing algorithms. Our algorithm explains more of the phenotypic variation (R2=0.27) than the IWPC pharmacogenomics (R2=0.15) or clinical (R2=0.16) algorithms. Among high-dose patients, our algorithm predicted a higher proportion of patients within 20% of stable warfarin dose (45% vs 29% and 2% in the IWPC pharmacogenomics and clinical algorithms, respectively). In contrast to our novel algorithm, a significant inverse correlation between predicted dose and percent West African ancestry was observed for the IWPC pharmacogenomics algorithm among patients requiring ⩾60 mg per week (β=−2.04, P=0.02).

[1]  E. Merriman,et al.  Bleeding risk with dabigatran in the frail elderly. , 2012, The New England journal of medicine.

[2]  G. Abecasis,et al.  A note on exact tests of Hardy-Weinberg equilibrium. , 2005, American journal of human genetics.

[3]  P. Ridker,et al.  A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans , 2010, Clinical pharmacology and therapeutics.

[4]  Christopher R. Gignoux,et al.  Development of a Panel of Genome-Wide Ancestry Informative Markers to Study Admixture Throughout the Americas , 2012, PLoS genetics.

[5]  Panos Deloukas,et al.  The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.

[6]  T. Langaee,et al.  Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. , 2004, Clinical chemistry.

[7]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[8]  N J Cox,et al.  The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics , 2012, Clinical pharmacology and therapeutics.

[9]  R. Kittles,et al.  Ancestral proportions and admixture dynamics in geographically defined African Americans living in South Carolina. , 2001, American journal of physical anthropology.

[10]  T. Langaee,et al.  Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans , 2010, Clinical pharmacology and therapeutics.

[11]  L. Cavallari,et al.  Association of Apolipoprotein E Genotype with Duration of Time to Achieve a Stable Warfarin Dose in African‐American Patients , 2011, Pharmacotherapy.

[12]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[13]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[14]  D. Sackett,et al.  The number needed to treat: a clinically useful measure of treatment effect , 1995, BMJ.

[15]  Roger Evans,et al.  IMS Institute for Healthcare Informatics , 2014 .

[16]  Yusuke Nakamura,et al.  Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study , 2013, The Lancet.

[17]  S. Goldhaber.  Pulmonary embolism in Black Americans , 2010, American journal of hematology.

[18]  F. Rosendaal,et al.  Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. , 2008, Pharmacogenomics (London).

[19]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[20]  Melissa A. Basford,et al.  Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. , 2012, Pharmacogenomics.

[21]  B. Horne,et al.  Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing , 2008, Journal of Thrombosis and Thrombolysis.

[22]  R. Kittles,et al.  Race, Skin Color and Genetic Ancestry: Implications for Biomedical Research on Health Disparities , 2007 .

[23]  R. Kittles,et al.  The relationship between “race” and genetics in biomedical research , 2007, Current hypertension reports.

[24]  M. Parker,et al.  Patient-Specific Factors Predictive of Warfarin Dosage Requirements , 2002, The Annals of pharmacotherapy.

[25]  D. Nicolae,et al.  The Missing Association: Sequencing‐Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans , 2011, Clinical pharmacology and therapeutics.

[26]  Derek J Van Booven,et al.  Polymorphism discovery in 51 chemotherapy pathway genes. , 2005, Human molecular genetics.

[27]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[28]  K. Weiss,et al.  Race, ancestry, and genes: implications for defining disease risk. , 2003, Annual review of genomics and human genetics.

[29]  B. Horne,et al.  A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II) , 2012, Circulation.

[30]  S. Goldhaber.  Risk factors for venous thromboembolism. , 2010, Journal of the American College of Cardiology.

[31]  R. Kittles,et al.  8q24 risk alleles in West African and Caribbean men , 2012, The Prostate.

[32]  D. Absher,et al.  Characterizing the admixed African ancestry of African Americans , 2009, Genome Biology.

[33]  Jaekyu Shin,et al.  Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. , 2011, Pharmacogenomics.

[34]  D. Wysowski,et al.  Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. , 2007, Archives of internal medicine.

[35]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[36]  Mark D Shriver,et al.  Control of confounding of genetic associations in stratified populations. , 2003, American journal of human genetics.

[37]  R. Ward,et al.  Informativeness of genetic markers for inference of ancestry. , 2003, American journal of human genetics.

[38]  Jaekyu Shin,et al.  Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants , 2011, Pharmacotherapy.

[39]  D. Allison,et al.  Estimating African American admixture proportions by use of population-specific alleles. , 1998, American journal of human genetics.

[40]  Nianjun Liu,et al.  VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. , 2008, Pharmacogenomics.